United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/505,336 03/21/2005		Lars Branden	1506-1075	7255
466 7590 06/20/2007 YOUNG & THOMPSON		EXAMINER		
	23RD STREET		LU, FRANK WEI MIN	
2ND FLOOR ARLINGTON			ART UNIT	PAPER NUMBER
AREINGTO	V, VA 22202		1634	
• .	e e		MAIL DATE	DELIVERY MODE
		• .	06/20/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application I	No.	Applicant(s)			
Office Action Summary		10/505,336		BRANDEN ET AL.			
		Examiner		Art Unit			
		Frank W. Lu		1634			
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS,							
WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1)⊠	Responsive to communication(s) filed on 8/23/	<u>2004</u> .					
2a) <u></u> ☐	This action is FINAL . 2b)⊠ This action is non-final.						
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Dispositi	ion of Claims						
4)🖂	Claim(s) 21-33 is/are pending in the application	ղ.					
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)	5) Claim(s) is/are allowed.						
•	Claim(s) is/are rejected.						
	Claim(s) is/are objected to.	alaatiaa raay	iromont				
8)[Claim(s) <u>21-33</u> are subject to restriction and/or	election requ	irement.				
Applicat	ion Papers						
9)[The specification is objected to by the Examine	r.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
11)	The oath or declaration is objected to by the Ex	aminer. Note	the attached Office	Action or form PTO-152.			
Priority (under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:							
	1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
dec the attached detailed office action for a list of the certified copies flot received.							
Attachmen							
	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948)	4)	Interview Summary Paper No(s)/Mail Da				
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date			Notice of Informal P Other:				

Art Unit: 1634

DETAILED ACTION

Preliminary Amendments

Page 2

1. The preliminary amendments filed on August 23, 2004 have been entered. The claims pending in this application 21-33.

Election/Restrictions

2. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 21-23, drawn to a method for the study of inter-molecular interactions under physiological or near-physiological conditions.

Group II, claims 24 and 31-33, drawn to drug candidates (claims 24 and 33) and drug delivery vectors (claims 31 and 32).

Group III, claim 25-28, drawn to a method for the production of a biomolecular complex.

Group IV, claims 29 and 30, drawn to a combinatorial library.

3. The inventions listed as Groups I to V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I, III, and IV and Group II do not relate to a single general inventive concept under PCT Rule 13.1 because the technical feature linking Groups I, III, and IV and Group II is

Art Unit: 1634

not special. For example, the drug candidates in claim 24 of Group II is not contribution over the prior art (see column 14, lines 50-67 and column 15, lines 1-7 of US Patent No. 6,420,532 B1). Although the drug candidates taught by US Patent No. 6,420,532 B1 is not made by a process of claim 21 of Group I, since claim 24 of Group II is a product-by-process claim, it is well established that even though product-by process claims are limited by and defined by the process, the determination of the patentability of the product is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process.

Groups I and III do not relate to a single general inventive concept under PCT Rule 13.1 because they lack the same or corresponding special technical features. For example, the study of inter-molecular interactions under physiological or near-physiological conditions in claim 21 of Group I is not required for Group III while the production of a biomolecular complex recited in claim 25 of Group III is not required for Group I.

Groups I and IV do not relate to a single general inventive concept under PCT Rule 13.1 because they lack the same or corresponding special technical features. For example, the study of inter-molecular interactions under physiological or near-physiological conditions in claim 21 of Group I is not required for Group IV while a combinatorial library recited in claim 29 of Group IV is not required for Group I.

Groups III and IV do not relate to a single general inventive concept under PCT Rule 13.1 because they lack the same or corresponding special technical features. For example, the

Art Unit: 1634

the production of a biomolecular complex recited in claim 25 of Group III is not required for Group IV while a combinatorial library recited in claim 29 of Group IV is not required for Group III.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Papers related to this application may be submitted to Group 1600 by facsimile 4. transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CAR § 1.6(d)). The CM Fax Center number is (571)273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Lu, Ph.D., whose telephone number is (571)272-0746. The examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached on (571)272-0735.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547. Much in

June 14, 2007

FRANK LU PRIMARY EXAMINER